1. Home
  2. LGN vs APLS Comparison

LGN vs APLS Comparison

Compare LGN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGN

Legence Corp.

HOLD

Current Price

$82.02

Market Cap

6.4B

Sector

N/A

ML Signal

HOLD

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$41.05

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGN
APLS
Founded
1963
2009
Country
United States
United States
Employees
7000
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
5.2B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
LGN
APLS
Price
$82.02
$41.05
Analyst Decision
Strong Buy
Hold
Analyst Count
17
21
Target Price
$59.50
$33.59
AVG Volume (30 Days)
1.5M
9.9M
Earning Date
05-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
112.50
EPS
N/A
0.15
Revenue
N/A
$1,003,782,000.00
Revenue This Year
$53.66
N/A
Revenue Next Year
$11.99
$18.19
P/E Ratio
N/A
$273.60
Revenue Growth
N/A
28.46
52 Week Low
$28.31
$16.83
52 Week High
$107.24
$41.14

Technical Indicators

Market Signals
Indicator
LGN
APLS
Relative Strength Index (RSI) 48.11 84.57
Support Level $77.55 $19.29
Resistance Level $107.24 $41.14
Average True Range (ATR) 5.84 0.06
MACD -1.83 -0.65
Stochastic Oscillator 15.97 58.33

Price Performance

Historical Comparison
LGN
APLS

About LGN Legence Corp.

Legence Corp is a provider of engineering, installation, and maintenance services for critical systems in buildings. It focuses on sectors that have technically demanding buildings, including technology, life sciences, healthcare, and education. Legence specializes in designing, fabricating, and installing complex heating, ventilation, and air conditioning (HVAC), process piping, and other mechanical, electrical, and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting, and building controls in existing facilities to enhance building performance, reliability, and efficiency. The services are mainly provided on a fixed price basis. The company has two reportable segments: Installation and Maintenance, which generates the maximum revenue, and Engineering and Consulting.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Share on Social Networks: